Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1

Fig. 2

Comparison of B3 Thymomas (TB3) (a to h) and Thymic Carcinoma (TC) (I to p) staining with Commercial Assays (CA) and Laboratory developed tests (LDT). HE staining (a, i); CA, PD-L1 22C3 PharmDx Dako (b, j); CA, Ventana PDL1 SP142 Assay (c, k); CA, Ventana PD-L1 S263 Assay (d, l); LDT PD-L1-E1L3N cell signaling technology (e, m); LDT PD-L1-SP142 Ventana (f, n); CA CD8-SP57 (g, o); CA PD1-NAT105 (h,p)

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us